That is the whole schedule as the FDA label states it.1 On the fastest pace the label allows, the first 5 mg dose comes in week 5, the first 10 mg dose in week 13 and the first 15 mg dose in week 21. The label sets a minimum time on each dose and no maximum, so a slower schedule is still on label.
The calculator below puts dates on every step from the day of your first dose. The rest of the page answers what the schedule leaves open. Do you have to go all the way to 15 mg? What did each dose deliver in the trials, and how do side effects change with the dose? What does the label say about slowing down, pausing or stepping back?
What is the Zepbound dosing schedule, with dates?
Enter the date of your first 2.5 mg dose and pick the maintenance dose you and your prescriber are heading for. The list shows the first and last dose of every step. Change the weeks on each dose to see a slower schedule.
The app keeps this schedule for you: it logs each dose and shows the date of the next step.
Open the appA calendar built from the label's minimum times. Your prescriber decides when and whether the dose changes.
Three details of the label wording matter for reading the list. The 4 weeks on 2.5 mg are fixed: the label says "for 4 weeks", and adds that 2.5 mg "is for treatment initiation and is not approved as a maintenance dosage". Every later step is worded differently: the dose "may be increased in 2.5 mg increments, after at least 4 weeks on the current dose". And the choice of where to stop belongs to the prescriber, who is told to "consider treatment response and tolerability when selecting the maintenance dosage".1
What are the six Zepbound doses, step by step?
Zepbound comes in six strengths, and each one has a place in the schedule. Three of them are maintenance doses. The other three exist to get you there in small steps.
| Dose | Weeks | First dose on day | What it is |
|---|---|---|---|
| 2.5 mg | 1 to 4 | 1 | Starting dose. Not a maintenance dose. |
| 5 mg | 5 to 8 | 29 | First maintenance dose. You can stay here. |
| 7.5 mg | 9 to 12 | 57 | Step between 5 and 10 mg. |
| 10 mg | 13 to 16 | 85 | Maintenance dose. For sleep apnea, the lowest one. |
| 12.5 mg | 17 to 20 | 113 | Step between 10 and 15 mg. |
| 15 mg | 21 onward | 141 | Maintenance dose and the maximum. |
The label names 5, 10 and 15 mg as the recommended maintenance doses for weight reduction. It does not list 7.5 or 12.5 mg among them, and it does not forbid staying on one of them either. Its only instruction for a dose that causes trouble is this: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage."1
The 20 weeks to reach 15 mg are the same in the main trial. SURMOUNT-1 assigned 2,539 adults to 5, 10 or 15 mg or placebo for 72 weeks, "including a 20-week dose-escalation period".2 Two later trials let people stop at the highest dose they could tolerate, and the label describes them the same way: doses "were escalated over a period of up to 20 weeks" to 10 or 15 mg.1 The schedule on the label is the schedule that was tested.
Why does Zepbound start at 2.5 mg?
The label gives one reason for the step-by-step schedule: "to reduce the risk of gastrointestinal adverse reactions".1 Nausea, diarrhea and vomiting are the most common side effects of the drug, and the label reports that most of these events "occurred during dose escalation and decreased over time".
Part of the explanation is in the pharmacology section. Zepbound slows the emptying of the stomach, and the label notes that this effect "was greatest after a single dose of 5 mg and diminished after subsequent doses". In other words, the body's reaction is strongest at the first exposure to a dose and fades with repetition. Starting low and waiting 4 weeks gives each step time to become routine before the next one.
There is also a trial that tested the question directly. Before the large studies, researchers gave 111 people with type 2 diabetes tirzepatide for 12 weeks on three different schedules. One group started at 4 mg and went up by 4 mg every 4 weeks, to 12 mg. Two groups reached 15 mg in 8 weeks with bigger jumps: one went 2.5, 5, 10, 15 mg, the other 2.5, 7.5, 15 mg. Nausea was reported by 24.1% of the 12 mg group, 39.3% and 35.7% of the two fast groups, and 7.7% on placebo. The authors concluded that "lower starting doses and smaller dose increments are associated with a more favourable side effect profile".3
The phase 3 trials then used the gentlest pattern of all: the lowest starting dose, the smallest step, 4 weeks apart. That design became the label.
When do I move up a dose?
Not before 4 weeks on the current dose. After that the label leaves the timing to you and your prescriber, and names the two things to weigh: how you are responding and how you are tolerating the dose.1
The 4-week minimum matches how the drug builds up. Tirzepatide has a half-life of about 5 days, so a weekly dose is only partly cleared when the next one arrives, and the amount in the body climbs for a few weeks before it levels off. The label states that "steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration". After 4 weeks on a dose you have felt nearly everything that dose will do, its side effects included. Moving up sooner would stack a new dose on a level that is still rising.
"Response" is easy to judge too early. In SURMOUNT-1, 18% of the people who took at least three-quarters of their doses had lost less than 5% of their weight by week 12, when they were on their third dose strength. Seven in ten of them had reached 5% by week 24 and nine in ten by week 72. On average it took them 25 weeks to get there.8 A slow first three months did not predict failure. It is one reason the label asks the prescriber to weigh response and tolerability together and does not set a weight target for moving up.
The chart below models that build-up through the whole schedule. It uses the label's half-life and time to peak, and shows the level as a share of where it settles on your maintenance dose.
A model, not a blood test: one compartment, half-life 5 days, peak at 24 hours, 100% is the settled weekly peak on the chosen maintenance dose. Dotted lines mark dose increases.
Two things stand out in the model. The level on 2.5 mg is a small fraction of the level on 15 mg, because the label reports that exposure "increases in a dose-proportional manner": six times the dose, six times the drug. And each 2.5 mg step is a smaller relative jump than the one before. Going from 2.5 to 5 mg doubles the dose. Going from 12.5 to 15 mg adds a fifth.
How much weight comes off during the climb?
More than half of the final result. The climb is often described as a waiting period before the "real" dose, and the trial curve says otherwise. The label prints the average weight of each group at every visit, and the visits at weeks 4, 8, 12, 16 and 20 fall on the last week of each step.1
| End of week | Dose in that week mg | Average loss | From 231 lb lb |
|---|---|---|---|
| 4 | 2.5 | 3.2% | 7 |
| 8 | 5 | 6.0% | 14 |
| 12 | 7.5 | 8.6% | 20 |
| 16 | 10 | 10.9% | 25 |
| 20 | 12.5 | 12.6% | 29 |
| 72 | 15 | 22.0% | 51 |
The 15 mg group of SURMOUNT-1, read from Figure 3 of the label: the average of people still in the trial at each visit. It ends at 22.0%, a little above the 20.9% in the results table, which counts everyone who was randomized.
By the end of week 20, before the first 15 mg dose, the group had lost 12.6% of its weight. That is more than half of what the same curve shows a year later. The group assigned to stay on 5 mg tells the same story from the other side: it stopped climbing in week 5 and its curve kept falling for more than a year, to 16.1% at week 72. Weight loss on this drug follows time on treatment at least as much as it follows the number on the pen. Our week-by-week chart has every visit for each dose.
Do I have to go all the way to 15 mg?
No. The label lists three maintenance doses, 5, 10 and 15 mg, and does not rank them. 15 mg is described only as the maximum.1 The trial tells you what each one delivered, and the gaps between them are uneven.
In SURMOUNT-1, the average weight loss at week 72 was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo.2 Doubling the dose from 5 to 10 mg added 4.5 points. The next 5 mg added 1.4. Put your own weight in to see the same numbers in pounds, or switch to the share of people who reached a given loss.
Weigh in once a week in the app and it plots your line against the trial average for your dose.
Open the appAll randomized participants, 2,539 adults without diabetes; starting weight in the trial averaged 231 lb (104.8 kg). Label Table 2.
The same pattern shows in the odds. A loss of 20% or more was reached by 30 in 100 people on 5 mg, 50 on 10 mg and 57 on 15 mg.1 The second step up buys less than the first, but it is not nothing: 7 more people in every 100 crossed the 20% line.
These are group averages, and a group is not a person. Some people on 5 mg lost more than the average on 15 mg, and the trial did not test whether a given person does better by moving up. It compared groups that were assigned a dose in advance. So the trial can tell you what to expect from each dose on average. The question of your own dose is answered over the following months, by your scale and your prescriber.
Do side effects get worse on higher doses?
Less than most people expect. In the two main trials together, stomach and bowel side effects were reported by 56% of people on each of the three doses, 5, 10 and 15 mg, against 30% on placebo.1 That total does not move with the dose. Individual symptoms move a little, and in different directions.
Studies 1 and 2 pooled: 2,519 people on Zepbound, 958 on placebo, up to 72 weeks. A side effect counted if it was reported at any time, at any severity.
Nausea was reported by 25, 29 and 28 of every 100 people on 5, 10 and 15 mg. Vomiting rose with the dose, from 8 to 11 to 13. Diarrhea rose slightly, from 19 to 21 to 23. Constipation went the other way: 17, 14 and 11.1
The clearest dose effect is in who gave up. Across both trials 4.8% of people on 5 mg, 6.3% on 10 mg and 6.7% on 15 mg stopped for good because of a side effect, against 3.4% on placebo. For stomach and bowel side effects alone the figures were 1.9%, 3.3% and 4.3%, against 0.5%. The label adds when it happened: most of those who stopped did so "during the first few months of treatment".1 That is the escalation period. Once people were settled on a dose, few left because of it.
One reading of these numbers is that the schedule works. Everyone in the 15 mg group passed through 5 and 10 mg on the way, and by the time they arrived their rate of nausea was no higher than that of people who stopped at 5 mg.
What happens if I stay on a lower dose?
You are on label, and you are in good company. The 5 mg group in SURMOUNT-1 never went higher, and after 72 weeks it had lost 15.0% of body weight on average, with 85 in 100 people losing at least 5% and 48 in 100 losing at least 15%.1 For comparison, the full 2.4 mg dose of Wegovy averaged 14.9% in its main trial.6
A newer trial tested stepping down on purpose. In SURMOUNT-MAINTAIN, 441 adults took tirzepatide at 10 or 15 mg for 60 weeks, and 378 of them were then assigned to stay on that dose, drop to 5 mg, or switch to placebo for another year. At week 112 the average loss from the starting weight was 21.9% for those who stayed on the higher dose, 16.6% for those who dropped to 5 mg and 9.9% for those switched to placebo.5
So a lower dose held most of the loss, though not all of it: about 5 points came back compared with staying put, and 12 points came back on placebo. The authors call the 5 mg step-down "a valuable alternative to discontinuation" and add that individual responses vary. The trial matters for the schedule because it shows the dose can move in both directions. Going up is not a one-way street.
Can the schedule be slowed down or paused?
Slowed down, yes, and without leaving the label. Every step after the first is worded as "after at least 4 weeks on the current dose". Six weeks, eight weeks or six months on a dose all satisfy "at least 4".1 Set the calculator at the top of the page to 6 or 8 weeks to see what that does to your dates: at 8 weeks per step, the first 15 mg dose moves from week 21 to week 37.
The Zepbound label has no instruction for slowing down because of side effects during the climb. The label of Wegovy, the other weekly injection approved for weight loss, does have one. It reads: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks."6 Zepbound's wording reaches the same place by a different route, since any step may last longer than 4 weeks.
Pausing is a different matter, and the label covers only the short version of it. A dose taken up to 4 days late still counts. After that, the dose is skipped and the next one is taken on the usual day. The label does not say what to do after several missed weeks, and it does not say at which dose to restart.1 That gap is real, so a restart after a longer break is a decision for your prescriber, who knows what you tolerated before.
What if I cannot tolerate the next step?
Then the previous dose can be your dose. The label's instruction is short: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage."1 Two of the large trials were built around exactly this situation. In SURMOUNT-3 and SURMOUNT-4 nobody was assigned a fixed dose. Doses were raised over a period of up to 20 weeks to what the label calls the maximum tolerated dosage, and that could be 10 mg or 15 mg. People who did not get on with 15 mg stayed at 10 mg and remained in the trial.
The numbers from those trials are a useful reference for how often the climb goes wrong. In SURMOUNT-4, 783 people started the drug and 14.4% of them had stopped before week 36, for any reason. Across the two main trials, between 4.8% and 6.7% of people stopped because of a side effect, depending on the dose.1 Put the other way round, more than nine in ten people did not stop because of side effects, and most of those who had trouble met it in the first months.
If a step up brings side effects that do not settle, the options the label and the trials support are these: stay longer on the current dose before trying again, go back to the last dose that was comfortable, or treat that dose as your maintenance dose if it is 5 or 10 mg. All three are choices to make with your prescriber. Severe or persistent stomach pain, repeated vomiting or signs of dehydration are different: the label lists them as reasons to contact a doctor promptly, at any dose.
Can I skip a step or start at a higher dose?
The label does not provide for either. It names one starting dose "for all indications", 2.5 mg, and one step size, 2.5 mg.1 There is no faster track for people who weigh more, who have taken a GLP-1 drug before, or who are switching from another brand.
The 12-week escalation study described above is the best evidence on bigger jumps. The two groups that reached 15 mg in 8 weeks, with steps of 5 and 7.5 mg, reported nausea at rates of 39.3% and 35.7%. The group that climbed in three equal steps to 12 mg reported 24.1%.3 The groups were small, 28 or 29 people each, so the exact figures are loose. The direction is not in doubt, and it is why the phase 3 trials chose the smallest step.
One situation comes up often: a prescription that starts at 5 or 10 mg because the person has already been taking tirzepatide under another name. Mounjaro is the same molecule in the same doses, approved for type 2 diabetes.7 A person who is settled on Mounjaro 10 mg and changes to Zepbound 10 mg has not skipped anything. The label itself does not discuss this switch, but the escalation exists to introduce the drug to the body, and that has already happened. If your first-ever tirzepatide prescription is above 2.5 mg, it is reasonable to ask the prescriber why.
Can I stay on 2.5 mg if it is working?
The label says 2.5 mg "is not approved as a maintenance dosage", and there is a reason beyond caution: nobody has tested it for longer than 4 weeks. In every large trial, people moved from 2.5 to 5 mg on schedule, so there is no 72-week result for 2.5 mg to compare with the others.
What exists is the first month. In SURMOUNT-1, where every group spent weeks 1 to 4 on 2.5 mg, the average loss at week 4 was 3.2% of body weight, against 1.1% on placebo.1 For someone starting at 231 lb that is about 7 lb. Our week-by-week chart shows what followed on each dose. A strong first month on 2.5 mg is a real effect of the drug. Whether it would have continued at that dose is unknown.
If you are losing steadily on 2.5 mg and do not want to move up, the conversation to have is about 5 mg, the lowest dose with long-term evidence, and about staying there.
What about doses below 2.5 mg?
The label lists none. The six strengths are 2.5, 5, 7.5, 10, 12.5 and 15 mg, in single-dose pens and vials and in the four-dose KwikPen, and each device delivers one of those six amounts.1 No published phase 3 trial of tirzepatide for weight loss used a dose under 2.5 mg, so there are no trial figures for weight, side effects or safety at smaller amounts.
"Microdosing" in online groups usually means drawing a smaller amount from a vial, often of a compounded product. That is outside anything the label or the trials describe, and it is not something this page can give numbers for. What the evidence does support is narrower: 5 mg is the lowest dose studied for long-term use, and the average result on it was a 15% loss.
What if I miss a dose during the schedule?
The label gives a 4-day window. If you miss a dose, take it "as soon as possible within 4 days (96 hours) after the missed dose". If more than 4 days have passed, skip it and take the next dose on your regular day. Either way you then go back to your normal weekly schedule.1
A late dose does not reset the count toward the next step by itself. The rule for moving up is time "on the current dose", and the label does not define how a skipped week counts. In practice a single late or skipped dose leaves you with less drug in your body for a few days, which is a reason to tell your prescriber before the next increase and no reason to double up. The label has no instruction to take two doses at once in any situation.
You can also move your injection day. The label allows it "as long as the time between the two doses is at least 3 days (72 hours)".1 Shifting from Friday to Monday is fine. Shifting from Friday to Saturday of the same week is not.
Do pens, vials and the KwikPen follow the same schedule?
Yes. The schedule is about milligrams, and every form of Zepbound comes in the same six strengths.1 What differs is how many doses a device holds and how you measure them.
| Form | Doses inside | Volume per dose mL | Strengths mg |
|---|---|---|---|
| Single-dose pen | 1 | 0.5 | 2.5 to 15 |
| Single-dose vial | 1 | 0.5 | 2.5 to 15 |
| KwikPen | 4 | 0.6 | 2.5 to 15 |
| Multi-dose vial | 4 | 0.6 | 2.5 to 15 |
A pen delivers its dose with one press, so there is nothing to measure. A vial needs a syringe, and the label asks for one "capable of measuring a 0.5 mL or 0.6 mL dose" and a new syringe and needle for every injection. The KwikPen holds a month of one strength: four doses of the same number of milligrams. It carries a little extra liquid for priming, which is not a fifth dose. The label adds that the KwikPen "is not recommended for self-administration by those who are visually impaired".1
Because a KwikPen or a multi-dose vial contains four doses of one strength, a step on the schedule lines up with one device. Moving up means a new prescription at the new strength. The label says that when the form changes, for example from pens to vials, the patient should be trained again on the new one.
Is the schedule different for sleep apnea?
The climb is the same and the destination is higher. Zepbound is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity. The starting dose and the steps are identical "for all indications". For sleep apnea the recommended maintenance dose is 10 mg or 15 mg; 5 mg is not listed for this use.1 On the fastest schedule that means at least 12 weeks before the first maintenance dose, against 4 weeks when the goal is weight loss alone.
Does anything else change the schedule?
Kidney and liver disease do not. The label recommends no dose adjustment for either, and reports that tirzepatide levels were unchanged in people with kidney impairment, including those on dialysis. It does ask for kidney function to be checked in anyone who has side effects that can cause dehydration, such as prolonged vomiting or diarrhea.1
Three kinds of medicine interact with the steps themselves.
Birth-control pills. Because Zepbound slows the stomach, it can reduce how much of a pill is absorbed, most of all right after a dose change. The label advises women on oral contraceptives "to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation".1 On the fastest schedule to 15 mg there is a dose change every 4 weeks for 20 weeks, so those windows join into one stretch of 24 weeks. Turn on the pill option in the calculator at the top to see your own dates. Contraceptives that are not swallowed, such as an IUD, implant, patch or ring, "should not be affected".
Insulin and sulfonylureas. Taken together with Zepbound, these diabetes medicines can push blood sugar too low. The label says their dose may need to be reduced, which is a decision for whoever prescribes them, ideally before each step up.1
Medicines where the exact level matters. The label names warfarin as an example and asks for monitoring when such drugs are taken with Zepbound. If you take a medicine like that, each dose increase is a moment to ask whether a check is due.
How long do I stay on the maintenance dose?
The label describes Zepbound as a treatment "to reduce excess body weight and maintain weight reduction long term", and sets no end date.1 The trial behind that wording is SURMOUNT-4.
In it, 783 adults started tirzepatide and took it for 36 weeks at the highest dose they tolerated, 10 or 15 mg. The 670 who completed that period had lost 20.9% of their weight on average. They were then assigned, without knowing which, to keep taking it or to switch to placebo for a year. Those who continued lost a further 5.5%. Those switched to placebo regained 14.0%.4 The gap between the two groups after one year was 19.4 points.
Together with the step-down trial above, this gives three tested paths after the climb: stay on the dose, drop to 5 mg, or stop. Each has a number attached. Staying kept the loss and added to it. Dropping to 5 mg kept about three-quarters of it. Stopping gave back more than half within a year. Which path fits is a decision about cost, side effects and goals, and it does not have to be made on the day you reach your dose.
How does the Wegovy schedule compare?
Wegovy injections also start low and climb every 4 weeks, with a different shape. There are four steps before the maintenance dose and they are not equal: 0.25 mg, 0.5 mg, 1 mg and 1.7 mg, each for 4 weeks, then 2.4 mg from week 17. The label allows 1.7 mg as a maintenance dose as well. Since March 2026 it has one more step: people who have tolerated 2.4 mg for at least 4 weeks and need more weight loss may go up to 7.2 mg, the new maximum.6
| Zepbound | Wegovy injection | |
|---|---|---|
| Starting dose | 2.5 mg | 0.25 mg |
| Time on each step | at least 4 weeks | 4 weeks |
| First maintenance dose | 5 mg, week 5 | 1.7 mg, week 13 |
| Top dose reached | 15 mg, week 21 | 2.4 mg, week 17; 7.2 mg, week 21 at the earliest |
| Top dose as a multiple of the start | 6 times | about 10 times for 2.4 mg, 29 times for 7.2 mg |
| Missed dose window | 4 days | until 2 days before the next dose |
The practical difference is where the first maintenance dose sits. On Zepbound it is the second dose strength, reached after one month. On Wegovy it is the fourth or fifth of six, reached after three or four months. A person who settles early on Zepbound is on a dose with 72 weeks of trial data behind it. Our head-to-head page covers what the two drugs delivered when they were compared directly.
What if I take too much?
The label's instruction is to call the Poison Help Line at 1-800-222-1222 or a medical toxicologist. It warns that symptoms may need to be watched for some time, "taking into account the half-life of tirzepatide of approximately 5 days".1 A double dose does not clear overnight: after 5 days half of it is still in the body. This is the other reason the label never suggests catching up by taking two doses.
What stays the same at every dose?
The routine around the injection does not change as the dose rises. The label's instructions are the same for 2.5 mg and for 15 mg.1
At every step
The upper arm comes with a condition: the label says another person should give an injection there. The three areas are interchangeable as far as the drug is concerned. The pharmacology section reports that "similar exposure was achieved" from the abdomen, thigh and upper arm, so a change of site does not change the dose you receive.
What is worth writing down at each step is short: the date and dose of every injection, the site, your weight once a week, and any side effect with the day it appeared. Four weeks of those notes are exactly what a prescriber needs to decide on the next step, and they answer the two questions the label asks: how you are responding and how you are tolerating the dose.
What should I ask before a dose increase?
The label gives the prescriber two things to consider, response and tolerability, and both are easier to discuss with numbers in hand. Five questions cover the decision.
- How much have I lost on this dose? Bring your weight from the first and the last week of the step. In the trial the average was about 2 to 3% of starting weight per 4-week step during the climb.
- Are my side effects fading or holding? Most stomach and bowel side effects in the trials came during the climb and eased with time. One that is still as strong in week 4 as in week 1 is worth mentioning before the dose rises.
- Is this dose a maintenance dose? 5, 10 and 15 mg are. If you are doing well on one of them, staying is an option the label names.
- Do any of my other medicines need a check? Insulin, sulfonylureas, warfarin and birth-control pills are the ones the label singles out.
- What happens if the next dose does not suit me? Agree in advance on the plan, waiting longer or stepping back, so that a rough week is not a surprise.
Short answers to common questions
Did my doctor make a mistake by keeping me on 5 mg?
No. 5 mg is a maintenance dose on the label, and the group that stayed on it in the main trial lost 15% of body weight on average over 72 weeks.
Is it normal to feel the drug less in week 4 than in week 1?
The label reports that the slowing of the stomach is strongest after the first dose and fades with later ones. Side effects follow the same course for most people. Weight loss in the trial continued through the weeks when side effects were fading.
Can I go back down after moving up?
The label says to "consider a lower maintenance dosage" when a dose is not tolerated. In SURMOUNT-MAINTAIN, people who dropped from 10 or 15 mg to 5 mg kept an average loss of 16.6% at week 112.
Does a heavier person need a higher dose?
The label does not adjust the dose for body weight. Everyone starts at 2.5 mg and the choice of maintenance dose rests on response and tolerability.
How long does one KwikPen last?
Four weeks. It holds four doses of one strength, which matches the shortest time the label allows on a dose.
Can I take my dose a day early to fit a trip?
Yes, as long as at least 3 days (72 hours) have passed since the previous dose.
How the calculators on this page work
The schedule calculator applies section 2.1 of the label: 4 weeks on 2.5 mg, then one 2.5 mg step at a time with the number of weeks you choose, never fewer than 4. The contraception dates apply section 7.2: 4 weeks from the first dose and from each increase.
The level chart is a model. It treats the body as one compartment, with the label's half-life of 5 days and median time to peak of 24 hours, and adds up the doses of the schedule you set. It shows the shape of the build-up. It cannot show your own blood level, which depends on body size and other factors the label describes.
The results chart uses Table 2 of the label, which reports SURMOUNT-1 for all randomized participants at week 72. The side-effect chart uses Table 1, which pools the two main trials. Percentages are converted to pounds or kilograms from the weight you enter and are rounded to whole numbers.
Sources
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2, 3, 5, 6, 7, 8, 10, 12 and 14, Tables 1 and 2. accessdata.fda.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
- Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 2020;22:938-946. doi:10.1111/dom.13979
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 2, Table 1. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information. Eli Lilly and Company; label text as published by the U.S. Food and Drug Administration, July 2026; sections 1 and 2. dailymed.nlm.nih.gov
- Ard J, Lee CJ, Gudzune K, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab 2025;27:5064-5071. doi:10.1111/dom.16554
Related analyses
Missed a dose of Zepbound or Wegovy? The label rule, checked against your dates
Wegovy dosing schedule: the injection, the new 7.2 mg dose and the tablets, with your dates
Your first week and first month on Zepbound: what to expect, by date
Mounjaro dosing schedule: 2.5 mg to 15 mg, week by week, with your own dates
Log each dose and see your next step by date.
Open Dose Insider